Onc Actu du 7 décembre 2016

	1. Biologie
Precision Oncology: Epigenetic Patterns Predict Glioblastoma Outcomes [NIH Director's Blog] An NIH-funded research team recently published in Nature Communications the most complete portrait to date of the epigenetic patterns characteristic of the glioblastoma genome.
Immune-Cell Traps May Aid Cancer Metastasis [NIH] For cancer cells that escape from the original tumor and travel to a distant location in the body, these so-called neutrophil extracellular traps (NETs) appear to help the cancer cells form tumors, or metastases, in other tissues, the research team reported.
	4.10 Dép., diag. & prono. - Poumon
Could a smartphone app help doctors diagnose lung cancer? [Cancer Research UK] “The app makes it much easier to plan nodule follow up in clinics and team meetings as you don’t have to wait for the website to load and it’s much more phone-screen-friendly. I’m a big fan!” said one user.
	5. Traitements
How mice are helping personalize cancer treatment [STAT] My company, Charles River Laboratories, is already testing cancer immunotherapies against tumors from more than 550 patients that have been transplanted into lines of humanized mice.
	5.12.2 Immunothérapies - CAR-T
Juno Needs to Back a Different CAR-T Horse [Bloomberg] Juno has another product, JCAR017, that looks to have fewer toxicity issues. It has a better chance to get to market and keep the company relevant. Juno had more than $1 billion in cash.
	5.13 WCLC
Opdivo (nivolumab) Alone or Combined With Yervoy (ipilimumab) Shows Encouraging Response and Survival Rates in Recurrent Small Cell Lung Cancer, From Phase 1/2 Study CheckMate -032 [BMS] Objective response rate with Opdivo plus Yervoy was 25% and was 11% with Opdivo monotherapy; in the combination arm, three patients experienced a complete response.
New Lung Cancer Tumor Staging Manual to Shape Lung Cancer Clinical Treatment [IASLC] The innovations introduced are based on the analyses of the new IASLC database that includes 70,967 evaluable patients with non-small cell lung cancer and 6,189 with small cell lung cancer.
Novartis announces Zykadia® first-line study results showing 16.6 month progression-free survival in patients with ALK+ advanced NSCLC [Novartis] Data will be used to support global regulatory submissions for first-line use of Zykadia in ALK+ advanced NSCLC patients.
Updated KEYTRUDA® (pembrolizumab) Data in Small Cell Lung Cancer and Mesothelioma Presented at 17th World Conference on Lung Cancer [Merck] Findings in Small Cell Lung Cancer and Malignant Pleural Mesothelioma Show Overall Response Rates of 33.3 Percent and 20.0 Percent, Respectively, in KEYNOTE-028.
In a rare blockbuster performance for AstraZeneca, Tagrisso comes through on lung cancer PhIII [EndPoints] The pharma giant is pulling back the veil off of new data demonstrating a 5.7-month improvement in progression-free survival of non-small cell lung cancer among patients with an epidermal growth factor receptor (EGFR) T790M mutation compared to platinum-based doublet chemotherapy (10.1 months vs 4.4 months).
KEYTRUDA® (pembrolizumab) Demonstrated Improved Health-Related Quality of Life Compared to Chemotherapy in First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) [Merck] First Presentation of Patient-Reported Outcomes from KEYNOTE-024 Study of Patients with Metastatic NSCLC Whose Tumors Have High PD-L1 Expression (Tumor Proportion Score [TPS] of 50 Percent or More).
Novartis' drug tops chemotherapy in untreated lung cancer patients [Reuters] Patients with anaplastic lymphoma kinase-positive (ALK+)advanced non-small cell lung cancer treated with Zykadia had a median progression-free survival of 16.6 months, compared to 8.1 months for those on chemotherapy.
	5.2.1 Pharma - Partenariats
AbbVie pens oncology research pacts with academic teams [FierceBiotech] AbbVie has struck five-year cancer research pacts with Johns Hopkins University School of Medicine and Northwestern University's Lurie Cancer Center. The similarly structured agreements give the academic centers access to new AbbVie therapies for use in preclinical research—and give the drug developer an option to license discoveries made by its new partners.
	5.3 Traitements - FDA, EMA, NICE...
EU clears Bristol-Myers immunotherapy drug for blood cancer [Reuters] Bristol-Myers Squibb's immunotherapy drug Opdivo has been approved in Europe for the treatment of classical Hodgkin lymphoma, a rare blood cancer, the U.S. company said on Wednesday.
	5.3.4 Traitements - AMM (FDA, EMA)
FDA Approves Genentech’s Avastin® (Bevacizumab) Plus Chemotherapy for a Specific Type of Advanced Ovarian Cancer [Genentech] Approval based on two large Phase III studies including GOG-0213 that showed a five month overall survival difference for women with platinum-sensitive recurrent ovarian cancer on Avastin plus chemotherapy compared to chemotherapy alone.
	5.8 ASH
ASH Roundup: CAR-T Shuffle, Hemophilia Updates, Checkpoint Progress & More [Xconomy] The cancer immunotherapy known as CAR-T was the star of the show, thanks to dazzling early data that showed more patients than not saw their leukemias and lymphomas knocked into remission by the living, genetically engineered cells.
	5.8.1 ASH - Communiqués
Kite Pharma Presents Results of Multi-Center Pivotal ZUMA-1 Trial of Axicabtagene Ciloleucel (KTE-C19) in Aggressive Non-Hodgkin Lymphoma as Late-Breaking Abstract at Annual Meeting of American Society of Hematology [Kite] Total of 111 Patients Enrolled and 101 Patients Treated Across More than 20 Sites in US and Israel.
Juno Therapeutics Highlights Progress with Best-in-Class Strategy in B-Cell Malignancies at ASH [Juno] “We are encouraged by the safety and efficacy results we are seeing with JCAR017 and JCAR014 in several B-cell malignancy settings, including in non-Hodgkin lymphoma, chronic lymphocytic leukemia, and pediatric acute lymphoblastic leukemia, and the possibilities suggested by early data in treating patients with CD19-negative disease.”
ARIAD Announces Data Presentations at American Society of Hematology Meeting [Ariad] - Final report from Phase 1 study of ponatinib includes approximately five-year median follow-up; Major Molecular Response (MMR) rate was 56 percent - Pooled Phase 1 and PACE analysis of CP-CML patients with T315I shows 83 percent estimated to maintain major cytogenetic response at four years
Phase III Studies Present Additional Evidence for REVLIMID® (lenalidomide) as Maintenance Therapy in Multiple Myeloma [Celgene] These studies were presented at the 58th American Society of Hematology (ASH) Annual Meeting in San Diego, Calif.
New Analysis Shows People with Cancer Who Received XARELTO® (rivaroxaban) for Blood Clots Had Fewer ER Visits and Lower Healthcare Costs than Those Given Standard Treatment [Johnson & Johnson] Economic and real-world research for XARELTO® in cancer-associated thrombosis (CAT) among other studies presented confirming the medicine’s safety and efficacy profile.
Late-Breaking Ibrutinib (IMBRUVICA®) Data Show Complete or Partial Response in Two-Thirds of Patients with Chronic Graft-Versus-Host-Disease, a Frequent and Potentially Life-Threatening Complication of Stem Cell Transplant [AbbVie] New Phase 2 data presented at the American Society of Hematology Annual Meeting highlight potential role of ibrutinib therapy beyond hematologic cancers.
	5.8.4 ASH - CAR T
At Late-Night ASH Talk, Juno Execs Look Beyond Stalled “Rocket” Trial [Xconomy] In an after-dinner review at the American Society for Hematology conference in San Diego, however, company executives spent most of their time touting other products in their pipeline for other cancers, in what sounded like the first step of a sharp pivot.
First Multicenter Trial Finds CAR T-Cell Immunotherapy Effective, Feasible for Hard-to-Treat Lymphoma [ASH] Interim analysis shows nearly six-fold higher rate of complete remission for refractory non-Hodgkin lymphoma with KTE-C19 compared to historical data.
	5.8.5 ASH - Myélome multiple
Additions to Standard Multiple Myeloma Therapy Do Not Appear to Yield Additional Benefit [ASH] Largest randomized trial finds second round of chemotherapy or stem cell transplant does not improve progression-free survival.
	5.8.6 ASH - Leucémies
IKZF1 Gene Mutations Found to Increase Hereditary Risk for Acute Lymphocytic Leukemia in Children [ASH] Inherited variants affect a protein involved in white blood cell development.
	6. Lutte contre les cancers
China is narrowing the U.S. lead in cancer research [FierceBiotech] China now has more than 17% of the global share of cancer research publications, up from around 5% in the mid-2000s, and now matches the output of the U.S. in 2005, according to a just-published report from science publisher Elsevier.
Reform regulations to make pet clinical trials easier [Nature] A forerunner of this trend, and a continuing gold standard, is the US National Cancer Institute’s Comparative Oncology Trial Consortium, which has been running for 12 years and recruits pet dogs into specific cancer trials.
	6.10.1 Politiques (USA)
ASCO Applauds House for Passing the STAR Act and Supporting Children with Cancer [ASCO] Since most childhood cancers are a collection of rare and ultra-rare diseases, there’s limited research available focused primarily on preventing, treating, and curing childhood cancer. The STAR Act encourages more extensive research into childhood cancers to pave the way for a better understanding of the unique characteristics of childhood cancers, as well as improved treatment options for patients.
With media watchdogs on the sidelines, pharma-funded advocacy groups pushed Cures Act to the finish line [HealthNewsReview] If the committee’s masterful sales job for the Cures Act is a textbook example of what constitutes effective PR and advocacy in Washington these days for legislation that may not be in the best interests of the public, press coverage offers a textbook example of media abdication of their watchdog role.
The FDA Is Not Hindering Medical Progress [Pacific Standard] Congress is trying to speed up Food and Drug Administration drug approvals, but the problem is science, not regulation.
New medical research bill aims to help early-career scientists [Science] The legislation authorizes NIH to establish a “Next Generation of Researchers Initiative” within the NIH Office of the Director to develop and coordinate policies and programs related to new researchers and earlier independence, such as funding opportunities, training and mentorship programs, and policies to enhance workforce diversity.
	6.11 Patients
Woman gives birth to own grandson as surrogate for her cancer survivor daughter [The Telegraph] Julie Bradford, 45, said she felt compelled to carry Jack for daughter Jessica Jenkins, 21, who was left unable to have children after suffering cervical cancer.